Online inquiry

IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5905MR)

This product GTTS-WQ5905MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL31RA gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001242636.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 133396
UniProt ID Q8NI17
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5905MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13891MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ8090MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ3005MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ2559MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ15526MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ5745MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ5611MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ12945MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PankoMab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW